Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
93.21
+1.04 (1.13%)
Jul 14, 2026, 4:00 PM EDT - Market closed
Inhibrx Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | 1.3 | 0.2 | 1.8 | 2.19 | 7.23 | |
Revenue Growth (YoY) | - | 550.00% | -88.89% | -17.88% | -69.69% | -43.89% |
Gross Profit | - | 1.3 | 0.2 | 1.8 | 2.19 | 7.23 |
Selling, General & Admin | 22.98 | 23.3 | 127.91 | 29.38 | 21.12 | 12.36 |
Research & Development | 101.37 | 113.03 | 203.74 | 191.64 | 110.19 | 71.44 |
Total Operating Expenses | 124.35 | 136.33 | 331.65 | 221.02 | 131.31 | 83.8 |
Operating Income | -123.05 | -135.03 | -331.45 | -219.22 | -129.12 | -76.56 |
Interest Income | 6.23 | 7.55 | 10.94 | 11.92 | 2.07 | - |
Interest Expense | -13.02 | -12.2 | -13.49 | -31.84 | -18.18 | -5.22 |
Other Non-Operating Income (Expense) | -0.34 | -0.38 | 2,022 | -0.58 | 0 | 0.01 |
Total Non-Operating Income (Expense) | -7.13 | -5.03 | 2,019 | -20.5 | -16.11 | -5.2 |
Pretax Income | -130.18 | -140.05 | 1,688 | -239.72 | -145.22 | -81.77 |
Provision for Income Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
Net Income | -130.19 | -140.06 | 1,688 | -241.36 | -145.23 | -81.77 |
Minority Interest in Earnings | - | - | - | 1.63 | - | - |
Net Income to Common | -130.19 | -140.06 | 1,688 | -243 | -145.23 | -81.77 |
Shares Outstanding (Basic) | 16 | 15 | 15 | 12 | 40 | 38 |
Shares Outstanding (Diluted) | 16 | 15 | 15 | 12 | 40 | 38 |
Shares Change (YoY) | 1.39% | 3.36% | 27.17% | -70.62% | 5.52% | 50.47% |
EPS (Basic) | -8.39 | -9.04 | 114.01 | -20.48 | -3.62 | -2.15 |
EPS (Diluted) | -8.39 | -9.04 | 112.62 | -20.48 | -3.62 | -2.15 |
Free Cash Flow | -131.94 | -129.83 | -197.01 | -197.9 | -115.99 | -81.19 |
Free Cash Flow Per Share | -8.50 | -8.38 | -13.15 | -16.80 | -2.89 | -2.14 |
Gross Margin | - | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | - | -10386.50% | -165724.00% | -12178.90% | -5890.37% | -1058.83% |
Profit Margin | - | -10773.50% | 843786.00% | -13408.90% | -6625.27% | -1130.80% |
FCF Margin | - | -9986.54% | -98503.00% | -10994.60% | -5291.38% | -1122.76% |
EBITDA | -120.71 | -132.54 | -329.16 | -218.03 | -127.89 | -75.37 |
EBITDA Margin | - | -10195.50% | -164582.00% | -12112.80% | -5834.49% | -1042.30% |
EBIT | -123.05 | -135.03 | -331.45 | -219.22 | -129.12 | -76.56 |
EBIT Margin | - | -10386.50% | -165724.00% | -12178.90% | -5890.37% | -1058.83% |
Effective Tax Rate | -0.00% | -0.00% | 0.00% | -0.00% | -0.00% | -0.00% |